Acne vulgaris - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Acne vulgaris - Pipeline Insight, 2021,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Acne vulgaris pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Acne vulgaris: Overview
Acne vulgaris is an inflammatory disorder of pilosebaceous unit, which runs a chronic course and it is self-limiting. It is classified into different forms which vary in severity, lesion type, and localization. It is a very common skin disorder which can present with inflammatory and non-inflammatory lesions chiefly on the face but can also occur on the upper arms, trunk, and back. Acne vulgaris is characterized by noninflammatory, open or closed comedones and by inflammatory papules, pustules, and nodules. Symptoms can be mild, moderate, or severe. Acne vulgaris is diagnosed clinically. Treatment for acne vulgaris based on severity and can involve a variety of topical and systemic agents directed at reducing sebum production, comedone formation, inflammation, and bacterial counts and at normalizing keratinization.
'Acne vulgaris - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acne vulgaris pipeline landscape is provided which includes the disease overview and Acne vulgaris treatment guidelines. The assessment part of the report embraces, in depth Acne vulgaris commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acne vulgaris collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Acne vulgaris report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acne vulgaris Emerging Drugs
Further product details are provided in the report..
Acne vulgaris: Therapeutic Assessment
This segment of the report provides insights about the different Acne vulgaris drugs segregated based on following parameters that define the scope of the report, such as:
Acne vulgaris: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Acne vulgaris therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acne vulgaris drugs.
Acne vulgaris Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Acne vulgaris - Pipeline Insight, 2021,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Acne vulgaris pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Acne vulgaris: Overview
Acne vulgaris is an inflammatory disorder of pilosebaceous unit, which runs a chronic course and it is self-limiting. It is classified into different forms which vary in severity, lesion type, and localization. It is a very common skin disorder which can present with inflammatory and non-inflammatory lesions chiefly on the face but can also occur on the upper arms, trunk, and back. Acne vulgaris is characterized by noninflammatory, open or closed comedones and by inflammatory papules, pustules, and nodules. Symptoms can be mild, moderate, or severe. Acne vulgaris is diagnosed clinically. Treatment for acne vulgaris based on severity and can involve a variety of topical and systemic agents directed at reducing sebum production, comedone formation, inflammation, and bacterial counts and at normalizing keratinization.
'Acne vulgaris - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acne vulgaris pipeline landscape is provided which includes the disease overview and Acne vulgaris treatment guidelines. The assessment part of the report embraces, in depth Acne vulgaris commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acne vulgaris collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Acne vulgaris R&D. The therapies under development are focused on novel approaches to treat/improve Acne vulgaris.
This segment of the Acne vulgaris report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acne vulgaris Emerging Drugs
- Twyneo: Sol-Gel Technologies
- BOS-356: Boston Pharmaceuticals
Further product details are provided in the report..
Acne vulgaris: Therapeutic Assessment
This segment of the report provides insights about the different Acne vulgaris drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Acne vulgaris
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Acne vulgaris: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Acne vulgaris therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acne vulgaris drugs.
Acne vulgaris Report Insights
- Acne vulgaris Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Acne vulgaris drugs?
- How many Acne vulgaris drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acne vulgaris?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acne vulgaris therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Acne vulgaris and their status?
- What are the key designations that have been granted to the emerging drugs?
- Sol-Gel Technologies
- Bausch Health Companies
- AOBiome
- Boston Pharmaceuticals
- Eligo Bioscience
- Suzhou Kintor Pharmaceuticals
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
- Vicuron Pharmaceuticals
- Galderma
- Twyneo
- IDP 126
- B 244
- BOS-356
- EB-005
- GT-20029
- Aminolevulinic acid
- NAI Acne
- Ivermectin topical
Introduction
Executive Summary
Acne vulgaris: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Acne vulgaris – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Acne vulgaris companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Acne vulgaris Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
IDP 126: Bausch Health Companies
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II/III)
Comparative Analysis
Ivermectin topical: Galderma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
BOS-356: Boston Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical/Discovery Stage Products
Comparative Analysis
EB-005: Eligo Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Acne vulgaris Key Companies
Acne vulgaris Key Products
Acne vulgaris- Unmet Needs
Acne vulgaris- Market Drivers and Barriers
Acne vulgaris- Future Perspectives and Conclusion
Acne vulgaris Analyst Views
Acne vulgaris Key Companies
Appendix
Executive Summary
Acne vulgaris: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Acne vulgaris – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Acne vulgaris companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Acne vulgaris Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
IDP 126: Bausch Health Companies
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II/III)
Comparative Analysis
Ivermectin topical: Galderma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
BOS-356: Boston Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical/Discovery Stage Products
Comparative Analysis
EB-005: Eligo Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Acne vulgaris Key Companies
Acne vulgaris Key Products
Acne vulgaris- Unmet Needs
Acne vulgaris- Market Drivers and Barriers
Acne vulgaris- Future Perspectives and Conclusion
Acne vulgaris Analyst Views
Acne vulgaris Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Acne vulgaris
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Acne vulgaris
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Acne vulgaris
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Acne vulgaris
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
